Study of Chemotherapy and Patient Health Outcomes for Nausea and Emesis (0000-041)

The purpose of this study is to assess whether timely feedback to providers on patient experiences with delayed chemotherapy induced nausea and vomiting (CINV) lead to differences in patient outcomes for subsequent cycles.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Chemotherapy Induced Nausea and Vomiting Pathological Conditions, Signs and Symptoms Signs and Symptoms Signs and Symptoms, Digestive Vomiting

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Highly or moderately emetogenic chemotherapy planned for at least 2 cycles

Exclusion criteria

Concurrent other anti-cancer therapy (e.g. radiation, hormone, etc.); vomiting during the 24 hours prior to first chemotherapy cycle; having a disease/condition or taking medication that may cause emesis

Treatment and study plan

Disease Management Assessment

Behavioral

Primary outcomes

CINV at the delayed phase during cycle 2

Secondary outcomes

Treatment for CINV

Sponsors and collaborators

Lead sponsor

Merck Sharp & Dohme LLC

Industry

Registry information

Official study title

Study of Chemotherapy and Patient Health Outcomes for Nausea and Emesis

Acronym: C-PHONE

Important dates

Study start: 2004
Primary completion: 2005
Study completion: 2005
First posted: Sep 21, 2005
Registry last updated: May 1, 2015

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed